DEF 14A: Ginkgo Bioworks Seeks Shareholder Approval for Reverse Stock Split and Charter Amendments

Ginkgo Bioworks is asking shareholders to approve a reverse stock split, officer exculpation, and charter updates at a special meeting on August 14, 2024.

Summary

• Ginkgo Bioworks is holding a special meeting of shareholders on August 14, 2024, to vote on several proposals.
• The primary proposal is to approve a reverse stock split of the company's Class A and Class B common stock at a ratio between 1:20 and 1:40, to be determined by the Board.
• The company is also seeking approval for officer exculpation and updates to the company's Amended and Restated Certificate of Incorporation.
• These updates include removing provisions related to the merger with Soaring Eagle Acquisition Corp. and the domestication process, which are no longer relevant.
• The record date for determining shareholders eligible to vote at the Special Meeting is June 24, 2024.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on outlining the proposals for the special meeting. While the need for a reverse stock split indicates underlying challenges, the document presents it as a strategic move to improve the company's position.

Positives

• The reverse stock split could increase the per-share price of Class A common stock, helping to maintain its listing on the NYSE.
• The reverse stock split could broaden the pool of investors and enhance liquidity.
• Reducing the number of outstanding shares may reduce fees and taxes paid to organizations and agencies.
• Officer exculpation may help attract and retain experienced and qualified officers.
• Charter updates streamline corporate actions and provide additional flexibility.

Negatives

• The reverse stock split may not increase the price of the Class A common stock.
• The market price of the Class A common stock may decrease due to factors unrelated to the reverse stock split.
• The reverse stock split may decrease the liquidity of the Class A common stock and result in higher transaction costs.
• The company may not satisfy the NYSE continued listing requirements following the reverse stock split.

Risks

• The reverse stock split may not increase the stock price, and it could potentially decrease.
• Failure to regain compliance with NYSE listing requirements could lead to delisting, negatively impacting liquidity and market price.
• The proposed reverse stock split may decrease the liquidity of the Class A common stock and result in higher transaction costs.

Future Outlook

The company aims to regain compliance with NYSE listing requirements within a six-month cure period. The Board may choose to implement the reverse stock split if it believes it is in the best interests of the company and its shareholders.

Management Comments

• Jason Kelly, CEO, expresses gratitude for shareholders' continued support.
• The Board believes that providing the flexibility for the Board to choose whether or not to effect the Reverse Stock Split and, if approved, to choose an exact split ratio will enable the Board to act in the best interests of the Company and its stockholders.

Industry Context

Reverse stock splits are often used by companies whose stock price has fallen below a certain threshold to maintain listing requirements on major exchanges. Officer exculpation is becoming more common as a way to attract and retain qualified executives.

Comparison to Industry Standards

• Many companies facing delisting from exchanges like the NYSE or NASDAQ have implemented reverse stock splits to boost their share price and regain compliance.
• For example, companies like Ocugen and CytoSorbents have recently undergone reverse stock splits to meet minimum price requirements.
• Officer exculpation is increasingly adopted by Delaware corporations following the 2022 amendment to DGCL Section 102(b)(7), aligning with practices at companies like Tesla and SpaceX which prioritize director and officer protection.

Corporate Governance

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, potentially seeing a change in the number of shares they own and the per-share price.
• Employees may benefit from the company's efforts to maintain its NYSE listing and attract investors.
• The reverse stock split could impact the marketability of the company's stock to certain potential investors.

Next Steps

• Shareholders to vote on the proposals at the Special Meeting on August 14, 2024.
• The Board will determine whether to implement the reverse stock split and at what ratio, if approved by shareholders.
• The company will file the Amended and Restated Charter with the Delaware Secretary of State if the proposals are approved.

Key Dates

Keywords

reverse stock split, officer exculpation, charter updates, proxy statement, shareholder meeting, Ginkgo Bioworks, NYSE, common stock